Related Experiment Video

Updated: Mar 22, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K

Antitumorigenic targets of cannabinoids - current status and implications

Robert Ramer1, Burkhard Hinz1

  • 1a Institute of Toxicology and Pharmacology , Rostock University Medical Center , Rostock , Germany.

Expert Opinion on Therapeutic Targets
|April 13, 2016
PubMed
Abstract

Insights

Cannabinoids show promise for cancer treatment by targeting the endocannabinoid system. These compounds exhibit antimetastatic, anti-invasive, and anti-angiogenic effects, offering a potentially safer therapeutic approach.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • The endocannabinoid system (ECS) is increasingly recognized for its role in cancer.
  • Molecular targets within the ECS are being explored for systemic cancer therapy.

Purpose of the Study:

  • To review the ECS's contribution to cancer progression.
  • To highlight preclinical data on cannabinoid-mediated anti-cancer mechanisms.

Main Methods:

  • Literature review of preclinical studies.
  • Focus on antimetastatic, anti-invasive, and anti-angiogenic effects of cannabinoids.

Main Results:

  • Cannabinoids demonstrate significant antimetastatic properties.
  • Evidence suggests cannabinoids inhibit cancer cell invasion and angiogenesis.
  • The ECS modulates multiple pathways involved in cancer progression.

Conclusions:

  • Targeting the ECS offers a promising strategy for systemic cancer treatment.
  • Cannabinoids possess a favorable safety profile.
  • Cannabinoid-based drugs could serve as novel 'antimetastatics'.
Keywords:
Angiogenesiscancercannabinoid receptorscannabinoidsendocannabinoidsmetastasistumor cell invasion

More Related Videos

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

3.0K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.3K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
927
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K